Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IMMUNE PHARMACEUTICALS, INC.

(IMNPQ)
SummaryQuotesChartsNewsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

IMMUNE PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Change in Directors or Principal Officers, Other Events (form 8-K)

04/13/2021 | 08:52am EST

Item 2.01. Completion of acquisition or disposition of Assets

On April 12, 2021 a new Nevada corporation was formed to merge and survive the bankrupt Immune Pharmaceuticals Inc (NJ).

The new corporation retains the same name however is registered in the state of Nevada. The company further has updated its address.

The new corporation is not subject to chapter 7 bankruptcy and has no association with any legal issues relating to the previous corporation.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors;

           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers



On April 13, 2021, Devin J Shaw, age 34, has been appointed as the Chief Finance Officer.

Mr. Shaw is an investment banker, predominantly specializing in Collateral trading, Equity & Debt capital market transactions.

In connection with his appointment to the board of Immune Pharmaceuticals as CFO, Mr Shaw's role Will entail planning and implementing all financial activities for the company.

The appointment as such carries no compensation and does not cover any expenses. This is subject to change once full employment has been agreed with the company.


Item 8.01. Other Events



The company is working on documents to bring up to date all SEC filings.

The company is also working on full employment contracts for the interim CEO to make this a permanent position and is further agreeing a contract with the new CFO. The market will be updated of this in the coming weeks.

The new Nevada corporation is a new entity unrelated to any events surrounding the previous bankruptcy.

The board will be announcing a new pharmaceutical asset once details have been finalized.

We will be applying to Finra once all SEC filings are up to date to have the "Q" status removed, we expect this corporate action to be initiated within 30 days.

Exhibit Number Description

  Exhibit 1        Certificate of charter
  Exhibit 2        Business license




-2-

© Edgar Online, source Glimpses

All news about IMMUNE PHARMACEUTICALS, INC.
04/13IMMUNE PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Change in..
AQ
04/12IMMUNE PHARMACEUTICALS INC : Change in Directors or Principal Officers, Other Events (form..
AQ
2020Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2020Motion For Case Conversion Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Approved for Immune Pharmaceuticals, Inc.
CI
2019Immune Pharmaceuticals, Inc. cancelled the transaction announced on October 9, 2018
CI
2019Motion for Case Conversion or Dismissal Filed for Immune Pharmaceuticals, Inc.
CI
2019Bidding Procedure Approved for Immune Pharmaceuticals, Inc.
CI
2019Motion for Asset Sale Filed by Immune Pharmaceuticals, Inc.
CI
2019Motion for Case Conversion Filed by Immune Pharmaceuticals, Inc.
CI
More news
Chart IMMUNE PHARMACEUTICALS, INC.
Duration : Period :
Immune Pharmaceuticals, Inc. Technical Analysis Chart | IMNPQ | US45254C2008 | MarketScreener
Managers and Directors
Adeel Ahmed-Daudpota President & Chief Executive Officer
Devin J. Shaw Chief Financial Officer
John Zhang Vice President-Research & Development
John A. Neczesny Independent Director
Jeffrey Paley Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNE PHARMACEUTICALS, INC.-90.00%0
JOHNSON & JOHNSON3.53%428 955
ROCHE HOLDING AG17.23%322 390
PFIZER, INC.44.09%288 950
NOVO NORDISK A/S65.08%245 091
ELI LILLY AND COMPANY45.45%223 321